Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Ascendis Pharma to $205 from $191 and keeps an Outperform rating on the shares following TransCon CNP data that the firm says roughly matches Voxzogo on efficacy. The firm’s new price target is based on an estimate for $450M in risk-adjusted TransCON CNP sales, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- BioMarin price target lowered to $90 from $118 at Truist
- BioMarin price target lowered to $115 from $130 at BofA
- Ascendis Pharma price target raised to $190 from $180 at Oppenheimer
- BioMarin price target lowered to $85 from $100 at RBC Capital
- BioMarin price target lowered to $87 from $115 at Stifel